U.S. News Room - Daiichi Sankyo US
WEB5 days ago · About Daiichi Sankyo ... This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s ...
Daiichi Sankyo launches first DTC ad for Enhertu, representing …
WEB1 day ago · As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first time in messaging efforts.. Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit as a whole — to educate patients about the drug’s expanded uses.
NHS England to offer Daiichi Sankyo’s quizartinib for AML
WEB2 days ago · In this article: 4568.T. The National Health Service (NHS) England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML) patients with the FLT3 ...
Daiichi Sankyo and MSD’s ADC improves progression-free …
WEB4 days ago · Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd antibody-drug conjugate (ADC) in patients with ...
Daiichi (4568 JP) Sets Sights on Next Generation of Targeted …
WEB5 days ago · September 16, 2024 at 5:00 PM EDT. Save. The Japanese cancer drug powerhouse Daiichi Sankyo Co. has its sights on the next generation of targeted oncology drugs, and this time it might not need a ...
Daiichi Sankyo posts positive DS-9606 clinical trial results in solid ...
WEB6 days ago · Daiichi Sankyo has reported positive initial findings from the dose escalation phase of the first-in-human Phase I trial of its investigational antibody drug conjugate (ADC) DS-9606 for treating ...
News Room - Daiichi Sankyo US
WEBDaiichi Sankyo Europe's Statement Regarding Esperion Therapeutics' Complaint. Industry Veteran, Dr. Mark Rutstein, Joins Daiichi Sankyo to Lead Global Oncology Clinical Development Program. Daiichi Sankyo, Inc. has taken measures to contribute to the overall effort to limit the spread of the virus that causes COVID-19.
Daiichi Sankyo and Merck Announce Global Development and ...
WEBOct 19, 2023 · Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R ...
WEBMar 22, 2021 · Daiichi Sankyo Initiates Phase 1/2 Clinical Trial for mRNA COVID-19 vaccine in Japan. Tokyo, Japan (March 22, 2021) – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) announced today it has started the first vaccinations in a phase 1/2 clinical trial in Japan of an mRNA vaccine (hereinafter, DS-5670) that is being developed by ...
Merck signs $5.5 billion deal with Daiichi for cancer therapy ...
WEBTOKYO, Oct 19 (Reuters) - Drugmaker Merck (MRK.N) will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22...
Skip to content